Related Experiment Video
Updated: Oct 21, 2025
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy
Olga Mucha1, Paulina Podkalicka1, Katarzyna Kaziród1
1Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Kraków, Poland.
Background:
Duchenne muscular dystrophy (DMD) is an incurable disease, caused by the mutations in the DMD gene, encoding dystrophin, an actin-binding cytoskeletal protein. Lack of functional dystrophin results in muscle weakness, degeneration, and as an outcome cardiac and respiratory failure. As there is still no cure for affected individuals, the pharmacological compounds with the potential to treat or at least attenuate the symptoms of the disease are under constant evaluation. The pleiotropic agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, have been suggested to exert beneficial effects in the mouse model of DMD. On the other hand, they were also reported to induce skeletal-muscle myopathy. Therefore, we decided to verify the hypothesis that simvastatin may be considered a potential therapeutic agent in DMD.
Methods:
Several methods including functional assessment of muscle function via grip strength measurement, treadmill test, and single-muscle force estimation, enzymatic assays, histological analysis of muscle damage, gene expression evaluation, and immunofluorescence staining were conducted to study simvastatin-related alterations in the mdx mouse model of DMD.
Results:
In our study, simvastatin treatment of mdx mice did not result in improved running performance, grip strength, or specific force of the single muscle. Creatine kinase and lactate dehydrogenase activity, markers of muscle injury, were also unaffected by simvastatin delivery in mdx mice. Furthermore, no significant changes in inflammation, fibrosis, and angiogenesis were noted. Despite the decreased percentage of centrally nucleated myofibers in gastrocnemius muscle after simvastatin delivery, no changes were noticed in other regeneration-related parameters. Of note, even an increased rate of necrosis was found in simvastatin-treated mdx mice.
Conclusion:
In conclusion, our study revealed that simvastatin does not ameliorate DMD pathology.
Insights
Simvastatin did not improve muscle function or reduce injury markers in Duchenne muscular dystrophy (DMD) mouse models. The study found no benefits and even noted increased necrosis, concluding simvastatin does not ameliorate DMD pathology.
Area of Science:
- Biomedical research
- Translational medicine
- Musculoskeletal disorders
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration due to mutations in the DMD gene.
- Current treatments for DMD are limited, necessitating the exploration of novel therapeutic agents.
- Statins, like simvastatin, have shown potential benefits in some DMD models, but also carry risks of muscle-related side effects.
Purpose of the Study:
- To investigate the efficacy of simvastatin as a potential therapeutic agent for Duchenne muscular dystrophy.
- To evaluate the effects of simvastatin on muscle function, injury markers, and regenerative processes in the mdx mouse model of DMD.
Main Methods:
- Assessment of muscle function using grip strength and treadmill tests.
- Measurement of muscle injury markers (creatine kinase, lactate dehydrogenase).
- Histological analysis including evaluation of inflammation, fibrosis, angiogenesis, and muscle regeneration.
Main Results:
- Simvastatin treatment did not improve running performance, grip strength, or single-muscle force in mdx mice.
- No significant changes in muscle injury markers, inflammation, fibrosis, or angiogenesis were observed.
- While a decrease in centrally nucleated myofibers was noted, simvastatin treatment led to an increased rate of necrosis in mdx mice.
Conclusions:
- Simvastatin does not demonstrate therapeutic benefits for Duchenne muscular dystrophy in the mdx mouse model.
- The findings suggest that simvastatin is not a suitable agent for ameliorating DMD pathology.
- Further research is needed to identify effective treatments for DMD.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...